We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$647M
AUM Growth
-$194M
Cap. Flow
-$64.4M
Cap. Flow %
-9.95%
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$20.4M
2
NKTR icon
Nektar Therapeutics
NKTR
+$14.1M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$8.7M
4
ESPR
Esperion Therapeutics
ESPR
+$6.56M
5
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
+$4.27M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12M
2
BIIB icon
Biogen
BIIB
+$8.66M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$3.63M
4
COGT icon
Cogent Biosciences
COGT
+$3.16M
5
INCY icon
Incyte
INCY
+$2.77M

Sector Composition

Rank Sector Weight
1 Healthcare 26.13%
2 Consumer Staples 0.17%
3 Financials 0.05%
4 Industrials 0.05%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$65.1M 10.06%
2,400
-7,467
-76% -$2.02M
BIIB icon
2
PUT
Biogen
BIIB
$30.9B
$62.9M 9.72%
2,451
+380
+18% +$107K
OEF icon
3
CALL
iShares S&P 100 ETF
OEF
$19.5B
$61.4M 9.49%
3,750
+1,250
+50% +$149K
SPY icon
4
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$54.2M 8.38%
+1,999
New +$540K
BIIB icon
5
Biogen
BIIB
$30.9B
$44.1M 6.82%
152,102
-30,796
-17% -$8.66M
NVO
6
PUT
Novo Nordisk
NVO
$228B
$28.7M 4.43%
+12,442
New +$296K
SRPT icon
7
CALL
Sarepta Therapeutics
SRPT
$1.64B
$28M 4.32%
2,117
-216
-9% -$20.4K
ESPR
8
PUT
DELISTED
Esperion Therapeutics
ESPR
$27.4M 4.23%
6,988
+935
+15% +$47.2K
NVO
9
Novo Nordisk
NVO
$228B
$19.8M 3.06%
+858,710
New +$20.4M
NVO
10
CALL
Novo Nordisk
NVO
$228B
$18.3M 2.83%
+7,944
New +$189K
NKTR icon
11
PUT
Nektar Therapeutics
NKTR
$2.39B
$14.5M 2.25%
198
+179
+942% +$206K
XNTK icon
12
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
$13.6M 2.1%
+1,429
New +$132K
ODT
13
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$12.8M 1.97%
578,599
-155,673
-21% -$3.63M
SRPT icon
14
PUT
Sarepta Therapeutics
SRPT
$1.64B
$12M 1.85%
908
+20
+2% +$1.89K
AZN icon
15
PUT
AstraZeneca
AZN
$269B
$11.8M 1.83%
1,683
-2,507
-60% -$180K
NKTR icon
16
Nektar Therapeutics
NKTR
$2.39B
$11.8M 1.83%
16,128
+12,206
+311% +$14.1M
AZN icon
17
CALL
AstraZeneca
AZN
$269B
$9.59M 1.48%
1,366
-5,957
-81% -$429K
XERS icon
18
Xeris Biopharma Holdings
XERS
$1.45B
$8.5M 1.31%
+447,686
New +$8.7M
COGT icon
19
Cogent Biosciences
COGT
$6.76B
$8.34M 1.29%
145,326
-65,637
-31% -$3.16M
ZGNX
20
CALL
DELISTED
Zogenix, Inc.
ZGNX
$7.62M 1.18%
1,723
-2,336
-58% -$96.3K
ESPR
21
DELISTED
Esperion Therapeutics
ESPR
$5.83M 0.9%
148,704
+129,881
+690% +$6.56M
SGMO
22
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.03M 0.78%
3,540
+154
+5% +$2.56K
XNTK icon
23
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
$4.76M 0.74%
500
-622
-55% -$57.3K
ONCE
24
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.53M 0.7%
547
-228
-29% -$17.6K
NTBL
25
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$4.08M 0.63%
+53,033
New +$4.27M
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management withdrew a net $64.4M in Q2 2018, closing 71 positions and reducing 42 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 16% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Novo Nordisk worth $19.8M.

  • Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
  • Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
  • Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
  • Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
  • Sabby Management opened 51 new positions and closed 71 in Q2 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.